NFKB1 and neoplasm: Here, we found that blocking NF-κB signaling pathway using JSH-23 attenuated the Id-1-induced tumor cell metastasis, provide novel evidence to support further explorations into the use of NF-κB inhibitors in NSCLC cancer therapy.